- Global Directory
- About the Experts portal
Following the executive order on 13 September to lower drug prices in the United States, the battleground over US healthcare is taking shape and could fundamentally impact the outlook of the global pharmaceutical industry—all while the coronavirus disease 2019 (COVID-19) pandemic continues to dominate the political agenda.
Vice President, Industry Services & Life Sciences, IHS Markit
Margaret Labban, Ph.D.
Life Sciences Senior Analyst, IHS Markit
Director, Life Sciences Research, IHS Markit
Managing Director - Consulting, Life Sciences, Economics and Country Risk, IHS Markit
Consulting Associate Director, Life Sciences, IHS Markit